Doxazosin

Drug Profile

Doxazosin

Alternative Names: Alfadil; Cardenalin; Cardular; Cardura; Cardura XL; Carduran; Dedralen; Diblocin; Doxaben; Doxazosin mesylate; Normothen; Supressin; Tensiobas; UK 33274; UK 3327427; Zoflux

Latest Information Update: 21 Sep 2011

Price : $50

At a glance

  • Originator Pfizer
  • Developer Almirall S.A.; AstraZeneca; Fisons; Libbs Farmaceutica; Lifepharma; Mylan; Pfizer; Purepac Pharmaceutical; Teva Pharmaceutical Industries
  • Class Antihypertensives; Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Hypertension

Most Recent Events

  • 25 Feb 2005 The US FDA has given final marketing approval for a sustained-release formulation of doxazosin in benign prostatic hyperplasia
  • 23 Nov 2004 A Pharmacoeconomic study has been added to the Men's Health therapeutic trials section
  • 02 Sep 2004 Health Canada has approved the combination treatment of finasteride and doxazosin in reducing the risk of symptomatic progress of benign prostatic hyperplasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top